- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: March 2018
- Public Summary Document (PSD) March 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) March 2018 PBAC Meeting - Word
Mepolizumab – March 2018
Mepolizumab: Powder for injection 100 mg; Nucala®
Last updated
13 July 2018